Vapotherm down 36% after Q3 revenue miss, guidance cut

Investors are punishing Vapotherm (VAPO -35.9%) after its Q3 revenue miss and softer guidance. Highlights:

Revenue: $10.8M (+15.1%).

Capital revenue down 7.0% due to fewer sales/leases of Precision Flow units and lower selling prices in the U.S.

Net loss: ($12.8M) (-34.7%); loss/share: ($0.65) (+94.0%).

Cash consumption (9 mo.): ($28.5M) (flat).

Q4 guidance: Revenue: $12.0M – 12.5M.

2019 guidance: Revenue: $47.1M – 47.6M from $49.0M – 51.0M.

Previously: Vapotherm EPS beats by $0.10, misses on revenue (Nov. 5)

https://seekingalpha.com/news/3515483-vapotherm-36-percent-q3-revenue-miss-guidance-cut

FDA OKs Aurobindo’s naloxone for opioid overdose

The FDA has approved Aurobindo Pharma’s (OTC:ARBQY) injectable Naloxone Hydrochloride for the treatment of opioid overdose.

https://seekingalpha.com/news/3515511-fda-oks-aurobindos-naloxone-opioid-overdose

Evolent up 14% after Q3 beat, guidance update

Evolent Health (EVH +14%) is up on double normal volume after its Q3 report released after the close yesterday. Highlights:

Revenue: $220.1M (+46.8%); Platform & operations services: $171.4M (+45.1%).

Net loss: ($25.5M) (-105.6%); loss/share: ($0.30) (-87.5%).

Non-GAAP EBITDA: $3,333M (-30.5%).

Cash consumption (9 mo.): ($55.8M) (-999%).

2019 guidance: Revenue: $838M – 850M from $825M – 850M; non-GAAP EBITDA: ($11.1M – 8.1M) from ($10.0M – 2.0M).

Previously: Evolent Health EPS beats by $0.03, beats on revenue (Nov. 5)

https://seekingalpha.com/news/3515551-evolent-14-percent-q3-beat-guidance-update

Care.com +4% after beats, in-line view

Care.com (NYSE:CRCM) is up 4% after this morning’s Q3 beats and in-line Q4 guidance, which sees revenue of $50.7-50.9M (consensus: $50.78M) and $0.17 EPS (flat with consensus).

U.S. consumer revenue grew 3% Y/Y in Q3 to $39.5M. Other businesses totaled $13.8M, up 29%.

Total members were up 14% to 35.2M and total families rose 16% to 20.6M.

Press release.

https://seekingalpha.com/news/3515623-care-com-plus-4-percent-beats-line-view

Vanda Pharmaceuticals EPS of $1.84

Vanda Pharmaceuticals (NASDAQ:VNDA): Q3 EPS of $1.84 may not be comparable to consensus of $0.07.

Revenue of $59.49M (+21.1% Y/Y) beats by $1.16M.

Press Release

https://seekingalpha.com/news/3515644-vanda-pharmaceuticals-eps-1_84

GenMark Diagnostics EPS misses by $0.01, beats on revenue

GenMark Diagnostics (NASDAQ:GNMK): Q3 GAAP EPS of -$0.20 misses by $0.01.

Revenue of $20.9M (+32.3% Y/Y) beats by $0.39M.

Press Release

https://seekingalpha.com/news/3515657-genmark-diagnostics-eps-misses-0_01-beats-revenue

Aimmune Therapeutics EPS in-line

Aimmune Therapeutics (NASDAQ:AIMT): Q3 GAAP EPS of -$1.03 in-line.

Cash, equivalents and investments of $200.5M

Press Release

https://seekingalpha.com/news/3515663-aimmune-therapeutics-eps-line